



THE JOURNAL OF
CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial

Author(s): Michael E. Thase, MD; Sagar V. Parikh, MD; Anthony J. Rothschild, MD; Boadie W. Dunlop, MD; Charles DeBattista, DMH, MD; Charles R. Conway, MD; Brent P. Forester, MD, MSc; Francis M. Mondimore, MD; Richard C. Shelton, MD; Matthew Macaluso, DO; James Li, PhD; Krystal Brown, PhD; Michael R. Jablonski, PhD; and John F. Greden, MD

DOI Number: <https://doi.org/10.4088/JCP.19m12910>


List of Supplementary Material for the article

1. [Figure 1](#) Patient flow-chart
2. [Table 1](#) Baseline demographics for patients in the intent-to-treat cohort who were included in analysis (taking medications with predicted gene-drug interactions at baseline) compared to those who were excluded (taking no medications with predicted gene-drug interactions at baseline)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Figure 1. Patient flow-chart



*All baseline medications were in the 'use as directed' report category

Supplementary Table 1. Baseline demographics for patients in the intent-to-treat cohort who were included in analysis (taking medications with predicted gene-drug interactions at baseline) compared to those who were excluded (taking no medications with predicted gene-drug interactions at baseline).

Characteristic	Included (N=912)	Excluded (N=629)	Total (N=1541)
Age (years)			
Mean (SD)	48.7 (14.7)	46.2 (14.2)	47.7 (14.5)
Min, Max	18, 90	18, 85	18, 90
Age Group, n (%)			
18 to 34	190 (20.8)	154 (24.5)	344 (22.3)
35 to 49	247 (27.1)	188 (29.9)	435 (28.2)
50 to 64	333 (36.5)	223 (35.5)	556 (36.1)
65 and Over	142 (15.6)	64 (10.2)	206 (13.4)
Sex, n (%)			
Female	646 (70.8)	433 (68.8)	1079 (70.0)
Male	266 (29.2)	196 (31.2)	462 (30.0)
Ethnicity, n (%)			
Hispanic or Latino	58 (6.4)	63 (10.0)	121 (7.9)
Not Hispanic or Latino	854 (93.6)	566 (90.0)	1420 (92.1)
Race, n (%)			
White	759 (83.2)	494 (78.5)	1253 (81.3)
Black	112 (12.3)	109 (17.3)	221 (14.3)
Asian	22 (2.4)	10 (1.6)	32 (2.1)
American Indian or Alaska Native	4 (0.4)	4 (0.6)	8 (0.5)
Native Hawaiian or Other Pacific Islander	0	2 (0.3)	2 (0.1)
Other or Multiple	15 (1.6)	10 (1.6)	25 (1.6)
HAMD-17			
Mean (SD)	20.52 (4.70)	20.77 (5.06)	20.62 (4.85)
Min, Max	6, 35	4, 37	4, 37
Depression Category, n (%)			
None (HAM-D17 0-7)	7 (0.8)	4 (0.6)	11 (0.7)
Mild (HAM-D17 8-13)	53 (5.8)	38 (6.0)	91 (5.9)
Moderate (HAM-D17 14-18)	236 (25.9)	162 (25.8)	398 (25.8)
Severe (HAM-D17 19-22)	313 (34.3)	198 (31.5)	511 (33.2)
Very Severe (HAM-D17 ≥ 23)	303 (33.2)	227 (36.1)	530 (34.4)
Failed Medication Trials			
Mean (SD)	3.63 (3.10)	3.29 (2.88)	3.49 (3.01)
Min, Max	1.0, 34.0	1.0, 25.0	1.0, 34.0
Psychiatric Comorbidities, n (%)			
General anxiety disorder	138 (15.1)	93 (14.8)	231 (15.0)
Panic disorders/social phobia	141 (15.5)	90 (14.3)	231 (15.0)
Post-traumatic stress disorder	43 (4.7)	33 (5.3)	76 (4.9)